EUVIMEDEUVIMED entdecken
Übersichtsarbeit

An Update on Bile Acid‐Regulated Signalling in the Pathogenesis of Metabolic Dysfunction‐Associated Steatotic Liver Disease

Jiang-Shan Shi, Yi Wen, Lu Wang, Li-Juan Wu, Li Wang, Chen Chen iD, Hong-Lian Wang iD, Chang-Ying Zhao

Liver International · 2026

DOI: 10.1111/liv.70586 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Liver International, 2026. Verfasst von Jiang-Shan Shi und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Integrated Chinese and Western Medicine, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, Sichu…. Hauptthemen laut MEDLINE: Bile Acids and Salts, Signal Transduction, Fatty Liver, Liver. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 201 Literaturangaben. Gefördert von: Science and Technology Department of Sichuan Province, Luzhou Science and Technology Bureau.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a common metabolic disorder with rising global incidence without effective treatment. Emerging evidence highlights bile acids (BAs) as pivotal signalling molecules that modulate genes involved in their own metabolism and lipid homeostasis in hepatic and extrahepatic tissues, thereby influencing MASLD pathogenesis. These regulatory effects are primarily driven by the activation of nuclear receptors, including the farnesoid X receptor (FXR), vitamin D receptor (VDR), pregnane X receptor (PXR), and by the membrane‐bound G protein‐coupled receptors such as Takeda G protein‐coupled receptor 5 (TGR5) and sphingosine‐1‐phosphate receptor 2 (S1PR2). The distinct roles of these BA receptor‐dependent signalling pathways in lipid homeostasis underscore their importance in MASLD development. Pharmacological strategies targeting BA‐regulated pathways, particularly the FXR activation, have shown promise in MASLD treatment. Several FXR agonists, including obeticholic acid (OCA), cilofexor, and tropifexor, have progressed to clinical trials, demonstrating potential therapeutic efficacy. Additionally, recent studies identified several natural compounds—such as hyperoside, kaempferol, and salidroside—that exhibited direct or indirect FXR‐modulating properties, suggesting their potential utility for novel anti‐MASLD drug development. Further research into BA signalling mechanisms and the exploration of targeted therapies may provide novel and effective MASLD therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bile Acids and SaltsSignal TransductionFatty LiverLiverHumansReceptors, Cytoplasmic and NuclearAnimalsReceptor, Farnesoid X-ActivatedReceptors, G-Protein-CoupledLipid Metabolism

Stichwörter der Autor:innen

MASLDbile acid signallingbile acidslipid metabolismnatural compoundtargeted therapy

Substanzen

Bile Acids and SaltsReceptors, Cytoplasmic and NuclearReceptor, Farnesoid X-ActivatedReceptors, G-Protein-Coupled

Autor:innen und Institutionen

  • College of Integrated Chinese and Western Medicine, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, Sichuan, China.
  • Research Center for Integrative Medicine, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, Sichuan, China.
  • Department of Endocrinology, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, Sichuan, China.
  • School of Biomedical Sciences, University of Queensland, St Lucia, Brisbane, Australia.

ORCID-Profile: Chen Chen, Hong-Lian Wang

Förderung

  • Science and Technology Department of Sichuan Province
  • Luzhou Science and Technology Bureau

Zitieren

APA

Shi, J. S., Wen, Y., Wang, L., Wu, L. J., Wang, L., Chen, C., Wang, H. L., & Zhao, C. Y. (2026). An Update on Bile Acid‐Regulated Signalling in the Pathogenesis of Metabolic Dysfunction‐Associated Steatotic Liver Disease. Liver International. https://doi.org/10.1111/liv.70586

Vancouver

Shi JS, Wen Y, Wang L, Wu LJ, Wang L, Chen C, et al. An Update on Bile Acid‐Regulated Signalling in the Pathogenesis of Metabolic Dysfunction‐Associated Steatotic Liver Disease. Liver International. 2026. doi:10.1111/liv.70586

BibTeX
@article{Shi2026,
  author = {Shi, Jiang-Shan and Wen, Yi and Wang, Lu and Wu, Li-Juan and Wang, Li and Chen, Chen and Wang, Hong-Lian and Zhao, Chang-Ying},
  title = {An Update on Bile Acid‐Regulated Signalling in the Pathogenesis of Metabolic Dysfunction‐Associated Steatotic Liver Disease},
  journal = {Liver International},
  year = {2026},
  doi = {10.1111/liv.70586}
}
Kostenlos starten →